OppenheimerFunds Inc. Raises Position in Aerie Pharmaceuticals Inc (AERI)

OppenheimerFunds Inc. boosted its position in shares of Aerie Pharmaceuticals Inc (NASDAQ:AERI) by 5.8% during the 2nd quarter, according to its most recent 13F filing with the SEC. The fund owned 319,850 shares of the company’s stock after purchasing an additional 17,415 shares during the quarter. OppenheimerFunds Inc. owned about 0.81% of Aerie Pharmaceuticals worth $21,605,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently made changes to their positions in AERI. American Century Companies Inc. grew its position in Aerie Pharmaceuticals by 67.7% during the 1st quarter. American Century Companies Inc. now owns 56,339 shares of the company’s stock valued at $3,056,000 after purchasing an additional 22,751 shares during the last quarter. Prudential Financial Inc. grew its position in Aerie Pharmaceuticals by 9.2% during the 1st quarter. Prudential Financial Inc. now owns 57,910 shares of the company’s stock valued at $3,142,000 after purchasing an additional 4,890 shares during the last quarter. Swiss National Bank grew its position in Aerie Pharmaceuticals by 2.5% during the 1st quarter. Swiss National Bank now owns 53,900 shares of the company’s stock valued at $2,924,000 after purchasing an additional 1,300 shares during the last quarter. Schwab Charles Investment Management Inc. grew its position in Aerie Pharmaceuticals by 10.8% during the 1st quarter. Schwab Charles Investment Management Inc. now owns 182,345 shares of the company’s stock valued at $9,893,000 after purchasing an additional 17,740 shares during the last quarter. Finally, Thrivent Financial for Lutherans grew its position in Aerie Pharmaceuticals by 1.3% during the 1st quarter. Thrivent Financial for Lutherans now owns 108,311 shares of the company’s stock valued at $5,876,000 after purchasing an additional 1,411 shares during the last quarter. 96.00% of the stock is currently owned by institutional investors.

In other news, insider Casey C. Kopczynski sold 11,000 shares of the stock in a transaction that occurred on Wednesday, August 1st. The shares were sold at an average price of $68.30, for a total value of $751,300.00. Following the transaction, the insider now owns 163,307 shares in the company, valued at approximately $11,153,868.10. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, COO Thomas A. Mitro sold 190,000 shares of the stock in a transaction that occurred on Monday, August 27th. The stock was sold at an average price of $60.27, for a total transaction of $11,451,300.00. Following the completion of the transaction, the chief operating officer now owns 234,147 shares in the company, valued at approximately $14,112,039.69. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 257,512 shares of company stock worth $15,670,247. Insiders own 10.53% of the company’s stock.

Shares of NASDAQ AERI opened at $59.15 on Monday. The company has a current ratio of 10.27, a quick ratio of 10.07 and a debt-to-equity ratio of 0.64. The stock has a market cap of $2.64 billion, a PE ratio of -17.55 and a beta of 0.77. Aerie Pharmaceuticals Inc has a 52-week low of $47.05 and a 52-week high of $74.75.

Aerie Pharmaceuticals (NASDAQ:AERI) last announced its quarterly earnings results on Wednesday, August 8th. The company reported ($1.14) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.98) by ($0.16). The firm had revenue of $2.42 million for the quarter, compared to analysts’ expectations of $1.16 million. equities research analysts forecast that Aerie Pharmaceuticals Inc will post -4.51 earnings per share for the current fiscal year.

Several analysts recently commented on the stock. Needham & Company LLC set a $86.00 price objective on shares of Aerie Pharmaceuticals and gave the company a “buy” rating in a research report on Friday, July 13th. BidaskClub raised shares of Aerie Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Saturday, June 23rd. ValuEngine raised shares of Aerie Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, August 14th. HC Wainwright set a $78.00 price target on shares of Aerie Pharmaceuticals and gave the company a “buy” rating in a report on Thursday, August 9th. Finally, Canaccord Genuity reaffirmed a “buy” rating and set a $86.00 price target on shares of Aerie Pharmaceuticals in a report on Friday, August 10th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and eleven have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average target price of $83.10.

Aerie Pharmaceuticals Company Profile

Aerie Pharmaceuticals, Inc, an ophthalmic pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma and other eye diseases. Its lead product is Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension.

Featured Story: Hedge Funds – Risk or Reward?

Institutional Ownership by Quarter for Aerie Pharmaceuticals (NASDAQ:AERI)

Receive News & Ratings for Aerie Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply